Of the 20 OEM-related M&A announcements we've covered in 2019 thus far, seven have related to the spine market. Of those, three were announced in rapid succession within this quarter. Let's see who bought whom, and what they got: Medtronic/Titan Spine, Boston Scientific/Vertiflex and WishBone Medical/CSpine.
Axolotl Biologix, a developer of regenerative medicine products, was acquired by a private equity firm. The company is preparing for FDA clinical trials of biologic products that have a range of applications in numerous segments, including orthopedics.
As was shown last week at AAOS, companies are taking strides to connect their devices with technologies that support improved patient outcomes. That connection can come in the form of M&A activity - which certainly applies to transactions announced over the month of March in joint replacement.
Stryker acquired OrthoSpace, maker of the InSpace device to treat rotator cuff tears, in an all-cash transaction for an upfront payment of US $110MM and future milestone payments of up to an additional $110MM.
Medacta and the Geisinger health system partnered to pilot a knee replacement lifetime guarantee, in which the pair will stand behind the full cost of care associated with surgeries over a patient's lifetime.
Smith & Nephew entered into an agreement to acquire Osiris Therapeutics, developer of regenerative medicine products including skin, bone graft and articular cartilage substitutes. The transaction is expected to close in 2Q19.
Merger and acquisition activity is shaping the broader orthopedic supply chain base, with contract manufacturers of all sizes transforming in the last decade to keep pace with their scaling device company customers. We've identified three M&A trends in this portion of the market.
We've tracked 31 mergers and acquisitions in the spine space from 2017 through mid-September 2018...with eight of them happening in just the last four weeks. The global spine market comprises nearly 300 companies; players need broad portfolios or novel technologies to vie for market share today.
DePuy Synthes signed a definitive agreement to acquire the assets of Medical Enterprises Distribution, developer of the ME1000 Surgical Impactor for use in hip replacement. The transaction is slated to close in 2Q18.
Integer entered into an agreement to sell its Advanced Surgical and Orthopedics lines to MedPlast, a global services provider to the medical device industry, for US $600MM in cash. The transaction is expected to close in 3Q18.
NuVasive entered into a definitive agreement to acquire SafePassage, provider of intra-op neurophysiological monitoring services. The company will join NUVA's Clinical Services business in a transaction slated to close in January 2018.
ORTHOWORLD estimates that global orthobiologic product sales account for ~10% of the orthopaedic market's revenue, overall. In 2016, that translated to just over $4.9 billion, an increase of 3% vs. 2015. For 2017 and into 2019, we're projecting similar growth.
Supplier companies have been involved in 17 of the 33 mergers and acquisitions that have closed in the orthopaedic space as of August 15, according to our tracking of activity. This activity comes in direct response to device company consolidation.
Implanet announced integration of its Jazz Claw device into the Australian Register of Therapeutic Goods and entry into an exclusive partnership with Device Technologies for product distribution in Australia and New Zealand.
The U.S. hospital landscape steadily continues to be shaped by consolidation that is forced by competition, declining reimbursement and public and private payor cost and control measures. As these trends are expected to endure at least through the next decade, it's imperative that you understand what your hospital customer base will look like several years from now.
DePuy Synthes entered into an exclusive agreement with Pacira Pharmaceuticals for U.S. co-promotion of EXPAREL® local analgesic across its joint reconstruction, spine, sports medicine and trauma businesses.
The primary responsibility of the supply chain team post-M&A is the assurance of uninterrupted upstream and downstream product supply. These essential steps will assist you in identifying supply chain risk and developing a plan to minimize that risk.
Data collection is paramount to the success of any orthopaedic device. What happens to the much-coveted postmarket data/initiative during and after a merger or acquisition? We posed this question to Vicki Anastasi, Vice President & Global Head, Medical Devices & Diagnostics Research with ICON plc.
Spineway signed a 5-year agreement with TINAVI Medical for distribution of spinal implants and instruments in China. TINAVI's TiRobot™ is reported to be the only surgical robot capable of addressing surgery on all spinal regions.
Norgine Ventures entered into a definitive agreement to acquire SpineVision. The partnership will support SpineVision's research and development for commercialization of products combining dynamic stabilization and a minimally invasive, percutaneous approach, such as Flex+2 and LUMIS.
Ferring Pharmaceuticals acquired exclusive development and commercialization rights to Seikagaku's SI-6603 injectable condoliase, a potential treatment for lumbar disc herniation, for up to US $95.0MM in upfront cash plus milestone payments.
Biomedical Structures, manufacturer of biomedical textile implants with application in orthopaedics, was acquired by Confluent Medical Technologies, a contract manufacturer of Nitinol components and kyphoplasty balloons. Terms were not disclosed.
Wright Medical received a binding offer under which Corin Orthopaedics would acquire Wright's hip/knee business for 29.7MM in cash (~US $33MM). The proposed transaction is expected to close by early 4Q16.
During 1H16, seven of the eight largest orthopaedic device companies confirmed or completed acquisitions or divestitures spanning nearly every orthopaedic market segment. Here we present a full list of M&A transactions from the first half of the year.
Medtronic acquired Responsive Orthopedics, a start-up focused on sales of low-cost hip and knee replacements. A primary knee is slated for commercial U.S. availability within 1H17, followed by a primary hip in 1H18.
Histogenics acquired development and commercialization rights to NeoCart® for the Japanese market from its partner, Purpose Co. NeoCart autologous cell therapy is designed to treat knee cartilage defects.
Stryker acquired Stanmore Implants Worldwide in an all-cash transaction for £35.6MM (~US $52MM). Stanmore Implants' portfolio comprises patient-specific and off-the-shelf implant systems for limb salvage.
Lima Corporate entered into an Innovation Alliance Agreement with the Hospital for Special Surgery. New product co-developments include a Trabecular Titanium total elbow and an advanced acetabular cup.
Bioventus spent most of 2015 building an infrastructure to expand its surgical business. With trecent acqusitions, a sales and distribution plan in place and future plans for inorganic and organic growth, Bioventus executives now say that the company is positioning itself as an orthobiologics leader.
MiMedx completed its acquisition of Stability Biologics, provider of human tissue products serving the surgical, spine and orthopaedic sectors. Stability Biologics will operate as a wholly-owned subsidiary of MiMedx.
MiMedx signed a definitive agreement to acquire Stability Biologics for US $10MM in cash and stock. Stability Biologics provides human tissue products for the surgical, spine and orthopaedic industries. The transaction is expected to close in early 1Q16.
NuVasive entered into a definitive agreement to acquire Ellipse Technologies for US $380MM in cash, with a potential $30MM milestone payable in 2017. The transaction is slated to close in mid-1Q16. Ellipse posted 2015 revenue of ~$40MM, +54% vs. 2014.